- Home
- STSS vs NKTX Comparison
STSS vs NKTX Comparison
Compare STSS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- NKTX
- Stock Information
- Founded
- STSS 2017
- NKTX 2015
- Country
- STSS United States
- NKTX United States
- Employees
- STSS N/A
- NKTX N/A
- Industry
- STSS Medical/Dental Instruments
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- NKTX Health Care
- Exchange
- STSS Nasdaq
- NKTX Nasdaq
- Market Cap
- STSS 124.5M
- NKTX 147.7M
- IPO Year
- STSS 2022
- NKTX 2020
- Fundamental
- Price
- STSS $3.98
- NKTX $1.96
- Analyst Decision
- STSS
- NKTX Strong Buy
- Analyst Count
- STSS 0
- NKTX 5
- Target Price
- STSS N/A
- NKTX $13.50
- AVG Volume (30 Days)
- STSS 186.0K
- NKTX 1.1M
- Earning Date
- STSS 11-13-2025
- NKTX 11-07-2025
- Dividend Yield
- STSS N/A
- NKTX N/A
- EPS Growth
- STSS N/A
- NKTX N/A
- EPS
- STSS N/A
- NKTX N/A
- Revenue
- STSS $222,722.00
- NKTX N/A
- Revenue This Year
- STSS N/A
- NKTX N/A
- Revenue Next Year
- STSS N/A
- NKTX N/A
- P/E Ratio
- STSS N/A
- NKTX N/A
- Revenue Growth
- STSS N/A
- NKTX N/A
- 52 Week Low
- STSS $3.36
- NKTX $1.31
- 52 Week High
- STSS $1,248.27
- NKTX $3.81
- Technical
- Relative Strength Index (RSI)
- STSS 34.85
- NKTX 40.24
- Support Level
- STSS $3.65
- NKTX $1.85
- Resistance Level
- STSS $5.49
- NKTX $2.01
- Average True Range (ATR)
- STSS 0.39
- NKTX 0.13
- MACD
- STSS -0.00
- NKTX -0.04
- Stochastic Oscillator
- STSS 21.20
- NKTX 18.40
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.